<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:department>Immunity and Infection</gtr:department><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/818CD6C9-61EE-41F2-9F37-0C7A8F43E25D"><gtr:id>818CD6C9-61EE-41F2-9F37-0C7A8F43E25D</gtr:id><gtr:name>University of Birmingham</gtr:name><gtr:address><gtr:line1>Edgbaston Park Road</gtr:line1><gtr:line2>Edgbaston</gtr:line2><gtr:postCode>B15 2TT</gtr:postCode><gtr:region>West Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/1A4F364A-A660-4ED7-A29F-AE45BDF1A36B"><gtr:id>1A4F364A-A660-4ED7-A29F-AE45BDF1A36B</gtr:id><gtr:firstName>Gwilym</gtr:firstName><gtr:otherNames>James</gtr:otherNames><gtr:surname>Webb</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role><gtr:role><gtr:name>FELLOW</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=MR%2FM001911%2F1"><gtr:id>F626F303-5188-4B44-BE1D-B17AE1462537</gtr:id><gtr:title>The roles and control of CD4+ effector and regulatory T-cells in biliary autoimmunity.</gtr:title><gtr:status>Active</gtr:status><gtr:grantCategory>Fellowship</gtr:grantCategory><gtr:grantReference>MR/M001911/1</gtr:grantReference><gtr:abstractText>When the body's own immune system damages part of the body, this is known as autoimmunity. Autoimmunity affecting the ducts that drain bile from the liver causes scarring over time and eventually results in jaundice and a need for liver transplantation. There are two major autoimmune bile duct diseases affecting patients: primary biliary cirrhosis and primary sclerosing cholangitis and, together, they lead to 10% of all liver transplants. At the present time, medicines for patients with these diseases are very limited. Although these conditions are a result of the body attacking itself, there is concern that treatments that suppress the body's own immune system can potentially be very dangerous, and associated with unpleasant side-effects. Our hope is that this research can lead to new treatments for patients that allow the immune system to be dampened down, without putting patients at risk of harm from, for example, infections.

To do this, our project is looking at how the immune system malfunctions and causes these diseases, particularly what goes wrong with the regulation of the immune system. By that, we mean that clearly in patients with autoimmune disease, the immune system is not able to regulate itself effectively, and instead of protecting the patient, is harming them.

Our group has a long standing interest in particular aspects of the immune system and has for some time worked with patient samples, as well as mice that get similar conditions. In this fellowship I will look closely at human liver tissue in particular, and map very carefully the location and nature of the immune cells that are damaging the liver. At the same time, using models of inflammation we have developed in mice, I will look to better understand how the inflammation is triggered and controlled, and more importantly ways that we can treat the inflammation.

Together this research is important because patients remain in need of new treatments. At the same time as completing these studies, I will personally also learn the skills needed to undertake research, a set of skills that all doctors benefit from having, as medicine becomes increasingly complicated and treatments personalised to the individual patient.</gtr:abstractText><gtr:technicalSummary>This project aims to characterise the immunopathology of the autoimmune biliary diseases (AIBD) primary biliary cirrhosis (PBC) and primary sclerosing cholangitis (PSC). It also aims to explore potential therapeutic options for AIBD by using the T-regulatory (Treg) deficient FoxP3KO mouse as a model.

We will survey archived explant liver tissue from AIBD patients. Using multiparameter confocal microscopy, we will characterise subtypes and spatial relations of the inflammatory infiltrate with particular attention to TH1, TH2, Treg and TH-17 cell populations. We will then assess peripheral blood lymphocyte populations using flow cytometry for similar patterns. 

We will evaluate FoxP3KO mice that develop peri-biliary inflammation and specific autoantibodies. We will then continue to assess how the disease of mice co-deficient in the tumour necrosis factor receptors OX40 and/or CD30 is ameliorated: we have previously shown that this ameliorates general phenotype but not explored hepatic manifestations. We will then explore the effects of OX40 and CD30 blockade via antibodies to their respective cognate ligands. In this instance, FoxP3KO T-cell transfer into lymphocyte deficient mice will be used as the model to ensure the recipients are large enough to allow antibody injection. Hepatobiliary disease will be assessed by liver histology, serum liver biochemistry, autoantibody indirect immunofluorescence and ELISA, and flow cytometric analysis of hepatic lymphocytes. 

We will then assess whether Treg transfer ameliorates liver disease in FoxP3KO mice by transfer of whole T-cell populations and using the methods described above. We will explore whether prior exposure to otherwise tissue-restricted antigen is important for Treg function by comparing AIRE-KO against wildtype donors. Finally we will compare Tregs from OX40 and/or CD30 deficient donors.</gtr:technicalSummary><gtr:potentialImpactText>Benefits and potential benefits are expected to the following groups from this research:
- Our work has a clear potential benefit to patients with primary biliary cirrhosis or primary sclerosing cholangitis: 10% of those requiring liver transplant and many not requiring transplant. Whilst precise figures are lacking, liver disease as a whole is estimated to cost the NHS &amp;pound;1/2 billion per year. Neither condition has a reliably effective treatment, and by investigating blockade of co-stimulatory molecules in an animal model of cholangitis, we aim to build a rational case for a clinical trial of these drugs (which have recently entered trials for other diseases and have a favourable safety profile). Such drugs have a real possibility of prolonging life and enhancing quality of life. Further, they have the potential to reduce the very significant healthcare costs of end stage liver disease and any success would reduce the burden on the over-stretched UK transplant programme - a major public health consideration. A realistic time course for early clinical translation of promising results is 2-3 years. Any consideration towards clinical exploitation of our work would be in consultation with our University's technology transfer company, 'Alta innovations'.
- Our proposed systematic survey of T-cell subtypes and co-stimulatory molecule expression will map the immunological phenotypes of these diseases, something which has not been done systematically before. This will enable ourselves and other researchers to consider other targeted therapies in these conditions. In turn, these targeted therapies have the potential to bring the benefits mentioned above. Our results will be communicated through publication. Whilst abstract and oral publications will be ongoing throughout the project, formal journal publication will take 2-3 years.
- Insights from one autoimmune condition may be applicable to others. Whilst we are working biliary autoimmunity, novel strategies of immune-contol may be applicable to the approximately 3% of the world population with autoimmune disease. 
- Our group has well-established links with the UK-PBC consortium, the PBC Foundation (www.pbcfoundation.org.uk), PSC Support and PSC Partners. These latter three patient charities actively support research and publish newsletters containing details of ongoing research for the benefit of their members. Details of our work will offered to them for dissemination.
- The fellowship itself offers an excellent platform for gaining new skills. It is anticipated that during the course of this fellowship, the proposer will continue to acquire familiarity with specific laboratory techniques including flow cytometry, confocal microscopy, histological preparation and interpretation, enzyme-linked immunosorbent assays, auto-antibody pattern assessment and interpretation. Further, more general scientific skills including written and spoken presentation of results, critical interpretation of the work of others, data analysis and statistical assessment, experimental design and implementation, collaborative skills and familiarity with the regulation and practice of animal studies. All of these skills are a great asset to continuing a career as a research-oriented hepatologist. These skills will be acquired during the course of the project but be useful throughout my career.
- Internally, the project represents a collaboration between the MRC Centre for Immune Regulation and Centre for Liver research/NIHR BRU. Although links are well-established, cross-fertilisation of ideas, investigation of the unique immunological environment in the liver and, importantly, furthering personal links between the departments will benefit the performance and working environment of both departments. Such benefits will build through the course of the project and persist after it has finished; they will also assist potential future researchers, especially fellows in a similar position to the proposer.</gtr:potentialImpactText><gtr:fund><gtr:end>2017-09-07</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2014-09-08</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>249319</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Public engagement event in the (Main foyer, Queen Elizabeth Hospital Birmingham)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>498D025A-A463-4C5A-8DF9-EDE798C8A003</gtr:id><gtr:impact>Manned exhibition stand in foyer of hospital. Demonstrated areas of research in liver disease. Fielded questions from general public</gtr:impact><gtr:outcomeId>56b74c00682f18.47814052</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.birmingham.ac.uk/research/activity/mds/centres/liver/BRU/past-events.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Participant at public engagement event for children (Birmingham ThinkTank)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>1022BD1A-E342-44C8-9FA5-B0D20AD92707</gtr:id><gtr:impact>Was a member of a team who designed and staffed stands demonstrating simple experiments relating to liver biology. This was set up in the local ThinkTank museum and primarily attended by children and their parents.</gtr:impact><gtr:outcomeId>56b74baa0eb551.83001993</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:url>http://www.birmingham.ac.uk/research/activity/mds/centres/liver/BRU/past-events.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Public engagement event (Palisades Shopping Centre, Birmingham)</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>8305CE9F-8C17-47E4-B268-13B4C08FC1BD</gtr:id><gtr:impact>For a number of days, the University of Birmingham rented retail premises in the Palisades Shopping Centre in Central Birmingham. This was opened to the public and involved discussion of current and future projects in liver-related research by the NIHR Centre for Liver Research.</gtr:impact><gtr:outcomeId>56b74c69475400.77665874</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Lecture at public engagement day for local secondary schools (Birmingham)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>509BA1A9-2553-46A1-8D9B-EB9C59CECB14</gtr:id><gtr:impact>Approximately 100 school students attended a day of explanation regarding medicine and potential careers in biomedical disciplines. I spoke to around half an hour and took questions afterwards. Positive feedback was obtained.</gtr:impact><gtr:outcomeId>56b74b3e0ecff6.06746711</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Schools</gtr:primaryAudience><gtr:url>http://www.birmingham.ac.uk/university/colleges/mds/outreach-widening-participation/medicine.aspx</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs><gtr:softwareAndTechnicalProductOutput><gtr:description>iPhone App that facilitated the calculation of the UK-PBC Risk Score (Carbone et al., Hepatology 2015)</gtr:description><gtr:id>78BC0EA2-0411-46A5-A253-B190E483ECC6</gtr:id><gtr:impact>A number of downloads worldwide</gtr:impact><gtr:outcomeId>56b74cc5e558c3.03235463</gtr:outcomeId><gtr:title>UK-PBC Risk Score Calculator</gtr:title><gtr:type>Software</gtr:type><gtr:url>http://www.uk-pbc.com/resources/tools/riskcalculator/</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput><gtr:softwareAndTechnicalProductOutput><gtr:description>iPhone app to facilitate the calculation of the UKELD score. The UKELD score is used in the UK to help prioritise patients for liver transplantation.</gtr:description><gtr:id>D1AA0470-9D07-4415-B6D6-E52B43DBF69B</gtr:id><gtr:impact>A number of downloads within the UK and worldwide.</gtr:impact><gtr:outcomeId>56b74d1a0417d0.79595316</gtr:outcomeId><gtr:title>UKELDcalc</gtr:title><gtr:type>Software</gtr:type><gtr:url>https://itunes.apple.com/us/app/ukeldcalc/id1054482028</gtr:url><gtr:yearFirstProvided>2015</gtr:yearFirstProvided></gtr:softwareAndTechnicalProductOutput></gtr:softwareAndTechnicalProductOutputs><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication><gtr:id>502FC7F7-6C7D-4CA1-A062-18F468145E8F</gtr:id><gtr:title>Modeling idiosyncrasy: a novel animal model of drug-induced liver injury.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56b74a9e99c926.76914668</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2CFEF018-2282-4D45-A422-5814DF11E415</gtr:id><gtr:title>Serum alkaline phosphatase in multidrug resistance 2 (Mdr2(-/-) ) knockout mice is strain specific.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/15e68c617b011357137d3bb9f8bef859"><gtr:id>15e68c617b011357137d3bb9f8bef859</gtr:id><gtr:otherNames>Trivedi PJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56b74a9d7462e1.00806703</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>54162119-EC9D-46B4-906E-A37C7552DB31</gtr:id><gtr:title>Cellular and Molecular Mechanisms of Autoimmune Hepatitis.</gtr:title><gtr:parentPublicationTitle>Annual review of pathology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1553-4006</gtr:issn><gtr:outcomeId>5a9e8b1075d003.23564202</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>97E51ECA-36EC-4B08-BC9B-AAA2F1FAA732</gtr:id><gtr:title>Twenty-Year Comparative Analysis of Patients With Autoimmune Liver Diseases on Transplant Waitlists.</gtr:title><gtr:parentPublicationTitle>Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>1542-3565</gtr:issn><gtr:outcomeId>5a9e8b0fe10613.74378977</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3CE49C09-CDE8-453C-9D5B-73D39B1C21FC</gtr:id><gtr:title>No Gains in Long-Term Survival After Liver Transplantation Over the Past Three Decades.</gtr:title><gtr:parentPublicationTitle>Annals of surgery</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/829fbac4b4e07fe8f30cdfa94f3e7fcf"><gtr:id>829fbac4b4e07fe8f30cdfa94f3e7fcf</gtr:id><gtr:otherNames>Rana A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0003-4932</gtr:issn><gtr:outcomeId>5a9e8b0f0b3106.68942241</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E63050E3-1977-45D2-8C89-75C170D4F288</gtr:id><gtr:title>OX40, OX40L and Autoimmunity: a Comprehensive Review.</gtr:title><gtr:parentPublicationTitle>Clinical reviews in allergy &amp; immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1080-0549</gtr:issn><gtr:outcomeId>56b74a9d480e71.05441768</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>D095B5B0-D4E2-4961-B2ED-56E60590AF31</gtr:id><gtr:title>Single-gene association between GATA-2 and autoimmune hepatitis: A novel genetic insight highlighting immunologic pathways to disease.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/831e3872a69b1eb56f7b45f7845ce099"><gtr:id>831e3872a69b1eb56f7b45f7845ce099</gtr:id><gtr:otherNames>Webb G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56b74a9caf14d9.56962227</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9B297E91-9895-4F7C-9A8E-2A60146BFBBE</gtr:id><gtr:title>Dynamic regulation of canonical TGF? signalling by endothelial transcription factor ERG protects from liver fibrogenesis.</gtr:title><gtr:parentPublicationTitle>Nature communications</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f32f7aeee5cce4602e029daa3e867ca0"><gtr:id>f32f7aeee5cce4602e029daa3e867ca0</gtr:id><gtr:otherNames>Dufton NP</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>2041-1723</gtr:issn><gtr:outcomeId>5a9e8b0f3cd417.43942910</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>440BDCEF-0177-41C8-90E2-EE04D7124B7E</gtr:id><gtr:title>Primary biliary cholangitis in 2016: High-definition PBC: biology, models and therapeutic advances.</gtr:title><gtr:parentPublicationTitle>Nature reviews. Gastroenterology &amp; hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>1759-5045</gtr:issn><gtr:outcomeId>58b57f186a3235.99416386</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>057D5CD3-7600-4B4F-82D5-33032A29A89E</gtr:id><gtr:title>Unmet clinical need in autoimmune liver diseases.</gtr:title><gtr:parentPublicationTitle>Journal of hepatology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/df2edbaa1215d66fb561f6798d413656"><gtr:id>df2edbaa1215d66fb561f6798d413656</gtr:id><gtr:otherNames>Dyson JK</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0168-8278</gtr:issn><gtr:outcomeId>56b74a9de588f2.89453682</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>9EF9180E-6E42-46A2-8F0E-A681E32E3F2F</gtr:id><gtr:title>Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study.</gtr:title><gtr:parentPublicationTitle>Alimentary pharmacology &amp; therapeutics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2018-01-01</gtr:date><gtr:issn>0269-2813</gtr:issn><gtr:outcomeId>5a9e8b1051b752.66477492</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>658990A3-250A-4D66-8210-672923B5B164</gtr:id><gtr:title>Using GWAS to identify genetic predisposition in hepatic autoimmunity.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>56b74a9cdf1b73.16609157</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E5D8758-9A6B-4C73-89AE-8D5B025432E6</gtr:id><gtr:title>Concurrent OX40 and CD30 Ligand Blockade Abrogates the CD4-Driven Autoimmunity Associated with CTLA4 and PD1 Blockade while Preserving Excellent Anti-CD8 Tumor Immunity.</gtr:title><gtr:parentPublicationTitle>Journal of immunology (Baltimore, Md. : 1950)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/354e41df85c56f1f434a0b15d5c5c066"><gtr:id>354e41df85c56f1f434a0b15d5c5c066</gtr:id><gtr:otherNames>Nawaf MG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0022-1767</gtr:issn><gtr:outcomeId>5a9e8b102a5e23.48919526</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>88857743-0335-4ADD-8F6E-CE4FB698473B</gtr:id><gtr:title>Genetics of autoimmune liver disease: a brief summary for clinicians.</gtr:title><gtr:parentPublicationTitle>Digestive diseases (Basel, Switzerland)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0257-2753</gtr:issn><gtr:outcomeId>56b74a9e200c31.45997656</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7E061C91-CEA4-4B4C-8188-E399DED0AA61</gtr:id><gtr:title>The etiology of intrahepatic cholestasis of pregnancy: towards solving a monkey puzzle.</gtr:title><gtr:parentPublicationTitle>The American journal of gastroenterology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>0002-9270</gtr:issn><gtr:outcomeId>56b74a9e6446b0.02819602</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>C52988D1-3423-41BE-9FA8-5181D5ADD8E2</gtr:id><gtr:title>Follicles, germinal centers, and immune mechanisms in primary biliary cirrhosis.</gtr:title><gtr:parentPublicationTitle>Hepatology (Baltimore, Md.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0270-9139</gtr:issn><gtr:outcomeId>56b74a9dbc85e9.29079186</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>87C66735-46EF-40FE-AC39-21F8F3A8C6F9</gtr:id><gtr:title>Low-dose interleukin-2 promotes STAT-5 phosphorylation, Tsurvival and CTLA-4-dependent function in autoimmune liver diseases.</gtr:title><gtr:parentPublicationTitle>Clinical and experimental immunology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/36771a91799f743bb0de0cf4570ac721"><gtr:id>36771a91799f743bb0de0cf4570ac721</gtr:id><gtr:otherNames>Jeffery HC</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2017-01-01</gtr:date><gtr:issn>0009-9104</gtr:issn><gtr:outcomeId>58b57f18377d14.52214253</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>7585472D-D0A4-4E1A-8FD1-6459776D4F60</gtr:id><gtr:title>The immunogenetics of primary biliary cirrhosis: A comprehensive review.</gtr:title><gtr:parentPublicationTitle>Journal of autoimmunity</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/7b1c8e42a1c207d430121c8b8bcf73a1"><gtr:id>7b1c8e42a1c207d430121c8b8bcf73a1</gtr:id><gtr:otherNames>Webb GJ</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0896-8411</gtr:issn><gtr:outcomeId>56b74a9d1c8c32.72635870</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">MR/M001911/1</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>C6D70A71-8796-47BC-AFE0-CC2286E66A06</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Inflammatory and Immune System</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1BF330A9-C7B5-49C5-B54B-CF4FAE6DF1D8</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>2.1  Biological and endogenous factors</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>